MD&A · 2025
In this section4 topics
Overview of Operations
Section Introduction
Overview of the Private Hospital and Healthcare Industry for 2025
Throughout 2025, Thailand’s private hospital and healthcare services industry continued to expand at a slower pace amid pressure from the modest domestic economic recovery, cautious consumer spending, and persistently high labor and medical supply costs. Nevertheless, demand for healthcare services remained structurally supported by Thailand’s transition into an aging society, the rising prevalence of non-communicable diseases (NCDs), and the growing emphasis on preventive and wellness care. These trends have prompted operators to rebalance their service mix toward higher-value offerings, while increasingly adopting digital technologies to enhance operational efficiency. Amid intensifying competition within the private hospital sector—driven by network expansion and continued investment in specialized medical services—the industry has clearly shifted from quantitative growth toward qualitative growth. In this context, the ability to effectively manage costs, maintain service quality, and expand into complex disease treatments or high-value medical services has become a critical determinant of long-term competitiveness and sustainability.
For Thonburi Healthcare Group Public Company Limited (“the Company”), operating performance during the period from 1Q2025 to 3Q2025 was impacted by the industry slowdown, as the Company’s patient base is primarily domestic and therefore sensitive to weakening purchasing power. However, in 4Q2025, seasonal disease outbreaks supported year-on-year growth in medical service revenue. Together with ongoing cost and expense management initiatives implemented throughout the year, the Company was able to generate a net profit, providing a solid foundation for the execution of its strategic plans in 2026. Looking ahead, the Company continues to prioritize cost discipline while expanding its domestic and international patient base, alongside the development of specialized and preventive healthcare services, to enhance revenue stability and long-term growth potential.
Overview of Operating Results for 4Q2025
In 4Q2025, the Company reported total operating revenue of THB 2,344.09 million, representing an increase of 4.00% YoY. The growth was primarily driven by hospital operating revenue, which increased by 6.38% YoY, supported by seasonal disease outbreaks. This was achieved despite a continued decline in international patient volumes, particularly from Cambodia, China, and the Middle East. A higher proportion of complex disease cases further reflected sustained patient confidence in the Company’s treatment capabilities. Revenue from other operations declined by 13.61% YoY, mainly due to the expiration of a heart center management contract with a public hospital at the end of 1Q2025, which is currently under a re-bidding process. Condominium transfers in 4Q2025 totaled 3 units, representing an increase of 1 compared with the same period last year.
The Company reported EBITDA of THB 485.70 million, representing an increase of 151.14% YoY, and net profit of THB 83.98 million, an increase of 105.75% YoY. The results included impairment expenses related to subsidiary assets totaling THB 21.46 million. Excluding these non-recurring items, normalized EBITDA amounted to THB 507.16 million, while normalized net profit totaled THB 101.08 million.
Overview of Operations
Overview of Operating Results for Full Year 2025
For the full year 2025, the Company recorded total operating revenue of THB 9,097.10 million, representing a decrease of 4.03% YoY. The decline was primarily attributable to negative publicity affecting customer confidence from late 2024 through 1Q2025, the domestic economic slowdown, a reduction in international patient volumes—particularly from Cambodia, China, and the Middle East—and the pending re-bidding of the heart center management contract with a public hospital, which expired at the end of 1Q2025. However, the impact was partially mitigated by higher other income, mainly from the sale of non-operating assets in 1Q2025, special dividend income received in 2Q2025, and the Company’s success in maintaining disciplined control over selling and administrative expenses.
As a result, the Company achieved EBITDA of THB 1,860.79 million, representing an increase of 1,511.05% YoY, while net profit amounted to THB 96.22 million, an increase of 105.45% YoY. Excluding non-recurring items, normalized EBITDA was THB 1,849.79 million, and normalized net profit totaled THB 84.80 million.
Operating Results & Financial Condition
Operating Results & Profitability
Analysis of Consolidated Operating Performance
Table 1: Consolidated Performance
Profit and Loss Statement (Unit : THB Million) | Consolidated Financial Statement | |||||
4Q2025 | 4Q2024 | Change (%) | FY2025 | FY2024 | Change (%) | |
Revenue from Hospital Operations | 2,111.93 | 1,985.26 | 6.38 % | 8,133.67 | 8,350.44 | (2.60 %) |
Revenue from Other Operations | 232.15 | 268.73 | (13.61 %) | 963.43 | 1,128.90 | (14.66 %) |
Total Operating Revenue | 2,344.09 | 2,253.99 | 4.00 % | 9,097.10 | 9,479.34 | (4.03 %) |
Cost of Hospital Operations | (1,579.07) | (2,042.20) | (22.68 %) | (6,208.52) | (6,821.42) | (8.98 %) |
Cost of Other Operations | (203.80) | (243.20) | (16.20 %) | (828.60) | (967.90) | (14.39 %) |
Total Cost of Goods and Services | (1,782.86) | (2,285.41) | (21.99 %) | (7,037.13) | (7,789.32) | (9.66 %) |
Gross Profit from Hospital Operations | 532.87 | (56.94) | 1,035.82 % | 1,925.15 | 1,529.02 | 25.91 % |
Gross Profit from Other Operations | 28.36 | 25.52 | 11.10 % | 134.83 | 161.00 | (16.25 %) |
Gross Profit from Operations | 561.22 | (31.42) | 1,886.33 % | 2,059.98 | 1,690.02 | 21.89 % |
Selling and Administrative Expenses | (423.42) | (1,178.94) | (64.08 %) | (1,726.56) | (2,485.12) | (30.52 %) |
Other Income / Expense (Net) | 11.58 | 42.83 | (72.97 %) | 152.16 | 122.04 | 24.69 % |
Share of Profit from Investment | 60.49 | 33.16 | 82.39 % | 202.95 | 175.81 | 15.44 % |
Net Gain/(Loss) - others | (3.74) | 11.98 | (131.19 %) | 32.47 | 3.76 | 662.74 % |
Expected Credit Losses | (6.27) | (122.34) | (94.87 %) | (17.57) | (564.58) | (96.89 %) |
Finance Cost | (54.58) | (116.54) | (53.17 %) | (376.13) | (492.77) | (23.67 %) |
Profit before Income Taxes | 145.29 | (1,361.27) | 110.67 % | 327.29 | (1,550.84) | 121.10% |
Income Taxes | (52.53) | (145.61) | (63.93 %) | (181.78) | (221.53) | (17.94 %) |
Net Profit for the Period | 92.76 | (1,506.88) | 106.16 % | 145.52 | (1,772.37) | 108.21 % |
Non-Controlling Interest | 8.79 | (45.35) | 119.37 % | 49.30 | (7.86) | 727.15 % |
Net Profit for the Period - Parent | 83.98 | (1,461.53) | 105.75 % | 96.22 | (1,764.51) | 105.45 |
Special Items
** In 3Q2024, There were ECL totaling to THB 442.23 million.
** In 4Q2024, There were ECL totaling to THB 122.34 million.
** In 4Q2024, an impairment loss of THB 807.88 million on assets of Thonburi Wellbeing. (Cost and SG&A)
** In 4Q2024, an impairment loss of THB 278.53 million on right-of-use assets of Thonburi Bamrungmuang Hospital. (Cost)
In 1Q2025, Gain on sale of non-operating land of Thonburi Hospital amounting to THB 40.67 million before income tax (THB 32.55 million after income tax).
In 2Q2025, Bad Debt of UCEP at Thonburi Bamrungmuang Hospital amounting to THB 12.13 million.
In 2Q2025, Impairment of non-operating building at the Thonburi Health Village Pracha Uthit amounting to THB 22.59 million.
In 2Q2025, Special dividend income from the entire business transfer of Thanakarn Hospital Co., Ltd. amounting to THB 44.39 million.
In 3Q2025, there were expenses related to the capital increase and debt restructuring totaling THB 17.86 million.
In 4Q2025, Additional Impairment of non-operating building at the Thonburi Health Village Pracha Uthit amounting to THB 7.91million.
In 4Q2024, an impairment loss of THB 8.99 million on asset of Rajyindee hospital.
In 4Q2024, an impairment loss of THB 4.57 million on assets of Thonburi Sermrath hospital
Revenue from Operations
The Company reported total operating revenue of THB 2,344.09 million in 4Q2025 and THB 9,097.10 million for the full year 2025, representing an increase of 4.00% YoY and a decrease of 4.03% YoY, respectively.
Consolidated Operating Revenue (Unit : THB Million) | 4Q2025 | 4Q2024 | Change (%) | FY2025 | FY2024 | Change (%) |
Revenue from Hospital Operations | 2,111.93 | 1,985.26 | 6.38 % | 8,133.67 | 8,350.44 | (2.60 %) |
Revenue from Sales of Goods | 49.20 | 50.79 | (3.14 %) | 218.91 | 233.99 | (6.44 %) |
Revenue from Other Services | 169.65 | 205.77 | (17.55 %) | 709.16 | 828.97 | (14.45 %) |
Revenue from Condominium Sales | 13.30 | 12.16 | 9.38 % | 35.36 | 65.93 | (46.37 %) |
Revenue from Hospital Operations amounted to THB 2,111.93 million in 4Q2025 and THB 8,133.67 million for the full year 2025, representing an increase of 6.39% YoY and a decrease of 2.60% YoY, respectively.
Revenue from Hospital Operations | 4Q2025 | FY2025 | ||
% Revenue Portion | % Change YoY | % Revenue Portion | % Change YoY | |
Inpatient Revenue – Net | 57% | 6.68 % | 56% | (4.65 %) |
Outpatient Revenue – Net | 43% | 1.62 % | 44% | (1.52 %) |
Inpatient and outpatient revenues increased by 6.68% and 1.62% YoY, respectively, in 4Q2025. The growth was driven by improved patient confidence following the successful capital increase completed in September 2025, changes in seasonal disease patterns compared with the prior year, and a recovery from the negative publicity in 4Q2024, which had previously weighed on patient volumes. For the full year 2025, inpatient and outpatient revenues declined by 4.65% and 1.52% YoY, respectively, primarily due to a significant reduction in international patient volumes—particularly from China, Cambodia, and the Middle East—together with the continued domestic economic slowdown, which led patients to defer non-urgent treatments. Nevertheless, patients requiring necessary medical care continued to demonstrate confidence in the quality of the Group’s hospitals, as reflected in a higher average revenue per inpatient day driven by an increased proportion of complex disease cases.
Revenue from Other Operations amounted to THB 232.15 million in 4Q2025 and THB 963.43 million for the full year 2025, representing declines of 13.61% YoY and 14.66% YoY, respectively. The decrease was primarily attributable to lower revenue from the management of a heart center at a public hospital following the expiration of the contract at the end of 1Q2025. Condominium sales at the Jin Wellbeing County declined by 46.37% in 2025, reflecting a lower number of cumulative unit transfers compared with the prior year (3 units in 4Q2025 vs 2 units in 4Q2024; 7 units in 2025 vs 12 units in 2024). In addition, revenue from product sales decreased by 6.44% YoY in 2025, mainly due to lower sales of dental equipment at subsidiaries.
Cost of Sales and Services
The Company reported cost of sales and services of THB 1,782.86 million in 4Q2025 and THB 7,037.13 million for the full year 2025, representing decreases of 21.99% YoY and 9.66% YoY, respectively, comprising the following components:
Cost of Hospital Operations (Unit : THB Million) | 4Q2025 | 4Q2024 | Change (%) | FY2025 | FY2024 | Change (%) |
Cost of Hospital Operations | 1,579.07 | 2,042.20 | (22.68 %) | 6,208.52 | 6,821.42 | (8.89 %) |
% To Revenue from Hospital Operations | 74.77 % | 102.87 % | 76.33 % | 81.69 % | ||
Cost of Hospital Operations - Normalized | 1,570.08 | 1,651.01 | (4.90 %) | 6,199.54 | 6,430.22 | (3.59 %) |
% To Revenue from Hospital Operations | 74.34 % | 83.16 % | 76.22 % | 77.00 % |
Cost of hospital operations amounted to THB 1,579.07 million in 4Q2025 and THB 6,208.52 million for the full year 2025, representing decreases of 22.68% YoY and 8.89% YoY, respectively. The decline was primarily attributable to special items recognized in 4Q2024 at Thonburi Wellbeing Company Limited and Thonburi Bamrungmuang Hospital Public Company Limited, including:
Impairment on buildings and intangible assets totaling THB 112.66 million (Total amount was THB 588.51
Impairment losses on right-of-use assets totaling THB 278.53 million.
Excluding special items in both 2024 and 2025, cost of hospital operations in 4Q2025 and for the full year 2025 would have decreased by 4.90% YoY and 3.59% YoY, respectively, reflecting improved cost control and operational efficiency across the Group, particularly at Thonburi Bamrungmuang Hospital. Special items in 4Q2025 included losses from write-offs and impairment of buildings, and equipment totaling THB 8.99 million, primarily resulting from flooding in southern Thailand.
Cost of Other Operations (Unit : THB Million) | 4Q2025 | 4Q2024 | Change (%) | FY2025 | FY2024 | Change (%) |
Cost of Other Operations | 203.80 | 243.20 | (16.20 %) | 828.60 | 967.90 | (14.39 %) |
% To Revenue from Other Operations | 87.8 % | 90.5 % | 86.0 % | 85.7 % |
Cost of other operations amounted to THB 203.80 million in 4Q2025, representing a decrease of 16.20% YoY, primarily due to lower service costs associated with the management of a heart center at a public hospital following the expiration of the contract at the end of 1Q2025.
Selling and Administrative Expenses (SG&A)
SG&A (Unit : THB Million) | 4Q2025 | 4Q2024 | Change (%) | FY2025 | FY2024 | Change (%) |
SG&A expense | 423.42 | 1,178.94 | (64.08 %) | 1,726.56 | 2,485.12 | (30.52 %) |
% To Total Revenue | 17.86 % | 51.67 % | 18.67 % | 25.88 % | ||
SG&A expense - Normalized | 415.51 | 510.09 | (18.54 %) | 1,683.22 | 1,816.27 | (7.60 %) |
% To Total Revenue | 17.52 % | 22.36 % | 18.14 % | 18.92 % |
The Company reported selling and administrative expenses of THB 423.42 million in 4Q2025 and THB 1,726.56 million for the full year 2025, representing decreases of 64.08% YoY and 30.52% YoY, respectively. The decline was primarily attributable to impairment losses totaling THB 668.85 million recognized by Thonburi Wellbeing Company Limited in the prior year, which were allocated to selling and administrative expenses, comprising:
Impairment on Project development costs for an integrated medical services project amounting to THB 219.37 million
Impairment on buildings and intangible assets totaling THB 449.48million (Total amount was THB 588.51
In addition, effective expense management contributed to a reduction in normalized selling and administrative expenses (excluding special items) of 18.54% YoY in 4Q2025 and 7.60% YoY for the full year 2025, reflecting the Company’s commitment to eliminating non-essential costs and enhancing operational efficiency.
Share of Profit from Associates and Joint Ventures
The Company reported share of profit from associates and joint ventures of THB 60.49 million in 4Q2025 and THB 202.95 million for the full year 2025, representing increases of 82.39% YoY and 15.44% YoY, respectively. The growth was primarily driven by the continued strong operating performance of ArYu International Hospital in the Republic of the Union of Myanmar, supported by growth in patient volumes, higher average spending per visit for outpatient services, and increased average revenue per inpatient day. Despite ongoing adverse foreign exchange impacts and the expiration of tax incentives, the share of profit continued to increase compared with the same period of the previous year.
Net Profit / (Net Loss)
In 4Q2025, the Company reported a net profit of THB 83.98 million, representing an increase of 105.75% YoY, or THB 1,545.51 million. Excluding all special items, normalized net profit amounted to THB 101.08 million, an increase of 137.01% YoY, or THB 374.17 million, compared with the same period of the previous year.
For the full year 2025, the Company recorded a net profit of THB 96.22 million, representing an increase of 105.45% YoY, or THB 1,860.73 million. Excluding special items, normalized net profit totaled THB 84.80 million, an increase of 154.75% YoY, or THB 239.67 million. The improvement was primarily driven by higher hospital operating revenue in 4Q2025, together with more effective cost and expense control throughout 2025. In addition, the financial restructuring completed in September 2025 contributed to a significant reduction in finance costs.
Analysis of Financial Position
Table 2: Comparison of the Company’s Financial Position
Financial Position | Consolidated Financial Statement | Separated Financial Statement | ||||
(Unit : THB Million) | 4Q2025 | 4Q2024 | Change (%) | FY2025 | FY2024 | Change (%) |
Current Assets | 3,223.80 | 3,088.22 | 4.39 % | 1,241.25 | 1,017.89 | 21.94 % |
Non-current Assets | 17,226.41 | 17,798.11 | (3.21 %) | 18,051.11 | 17,408.71 | 3.69 % |
Total Assets | 20,450.20 | 20,886.33 | (2.09 %) | 19,292.35 | 18,426.60 | 4.70 % |
Current Liabilities | 2,421.57 | 8,315.15 | (70.88 %) | 1,436.51 | 7,107.27 | (79.79 %) |
Non-current Liabilities | 3,496.20 | 4,310.45 | (18.89 %) | 3,137.08 | 3,387.88 | (7.40 %) |
Total Liabilities | 5,917.77 | 12,625.60 | (53.13 %) | 4,573.60 | 10,495.15 | (56.42 %) |
Total Shareholder Equity | 14,532.43 | 8,260.73 | 75.92 % | 14,718.76 | 7,931.45 | 85.57 % |
Assets as of 31 December 2025, total assets amounted to THB 20,450.20 million, representing a decrease of 2.09%% or THB 436.13 million compared to the end of 2024. The change was primarily attributable to the following factors:
Trade and other receivablesdecreased by THB 279.18 million, mainly due to collections from embassy and government receivables, together with the write-off of (UCEP) receivables at Thonburi Bamrungmuang Hospital during 2Q2025.
Short-term investmentsdecreased by THB 106.20 million, from the sale of investment units in mutual funds, as well as the transfer of shares in settlement of debt following the divestment of Ratchaphruek Hospital Public Company Limited.
Long-term investmentsdecreased by THB 104.60 million, from fair value adjustments through other comprehensive income.
Property, plant, right-of-use, and intangible assetsnetting with Investment propertiesdecreased by THB 522.09 million, mainly due to depreciation and amortization in accordance with accounting policies, as well as the termination of a land lease agreement
These movements were partially offset by an increase incash and cash equivalentsf THB 547.01 million, primarily arising from the remaining proceeds from the capital increases after the repayment of bank borrowings.
Liabilities as of 31 December 2025 amounted to THB 5,917.77 million, representing a decrease of 53.13%, or THB 6,707.82 million, compared to the end of 2024, mainly due to:
short-and long-term borrowings from financial institutions decreased by THB 5,982.70 million, while Debentures decreased by THB 105.02 million, following repayment and prepayment using capital increase proceeds.
Trade and other payables decreased by THB 373.82 million due to settlements of trade payables, payment of fixed asset purchases, and share transfers to settle debt with Ratchaphruek Hospital.
Shareholders’ equity as of 31 December 2025 totaled THB 14,532.43 million, representing an increase of 75.92%, or THB 6,271.70 million, compared to the end of 2024, mainly due to the capital increases through the PP and RO totaling THB 6,279.76 million, partially offset by an unrealized loss of THB 104.60 million from fair value adjustments of investments through other comprehensive income. Net profit during the period also contributed to the increase in shareholders’ equity.
Analysis of Cash flow statement
Table 3: Comparison of the Company’s Cash Flow Statement
Cash Flow Statement | Consolidated Financial Statement | Separated Financial Statement | ||
(Unit : THB Million) | FY2025 | FY2024 | FY2025 | FY2024 |
Net cash generated from/(used in) operating activities | 1,182.85 | 935.69 | 1,508.18 | 687.56 |
Net cash generated from/(used in) investing activities | (696.09) | (669.02) | (1,800.92) | (1,375.66) |
Net cash generated from/(used in) financing activities | 61.24 | (695.95) | 726.51 | 279.79 |
Net increase (decrease) in cash and cash equivalents | 548.00 | (429.28) | 433.77 | (408.31) |
Cash and cash equivalents at the beginning of period | 459.72 | 939.77 | 236.66 | 645.76 |
Unrealized exchange gain (loss) in cash and cash equivalents | (0.99) | (50.76) | (0.58) | (0.79) |
Cash and cash equivalents at the end of period | 1,006.73 | 459.72 | 669.85 | 236.66 |
Net cash generated from operating activitieswas THB 1,182.85million, an increase of THB 247.16million, mainly from improved working capital management and higher collection from embassy receivables at Thonburi Bamrungmuang Hospital.
Net cash used in investing activitieswas THB 696.09million, primarily from construction projects including the new inpatient building at Thonburi Hospital, Thonburi Thawiwatthana Hospital, the Radiation Therapy Center at Thonburi Trang Hospital, and Thonburi Lanta Medical Center. The Company also received a proceed from the sale of non-operating land and dividend income from long-term investments.
Net cash used in financing activitieswas THB 61.24million, resulting from receipt of capital increase proceeds totaling THB 6,249.73 million and repayment of bank loans and prepayment of debenture, together with subsidiary dividend payments and lease liability repayments.
Debt Securities with Financial Ratio Requirements
Debt Securities with Financial Ratio Requirements Issued?
Yes
Can the Company Maintain the Reported Financial Ratios?
Yes
Factors That May Affect Financial Condition
Factors or Incidents That May Materially Affect Financial Condition
Significant Events and Developments of the Company in 2025
Period | Significant Events and Developments |
May 2025 | On 20 May 2025, Thonburi Hospital officially opened its new eight-storey outpatient building (Building 8) under the concept “Hospital — We Are Ready at Thonburi.” The new facility enhances the Hospital’s capacity and improve the overall patient experience, supporting patient retention and repeat visits in line with the Hospital’s objectives of providing high-quality care with convenient access at a reasonable price cost, while maximizing patient satisfaction. |
June 2025 | THG received approval from the Extraordinary General Meeting of Shareholders No. 1/2025 held on 9 June 2025 to undertake the following actions:
|
August 2025 | THG received proceeds from the subscription of newly issued ordinary shares by Ramkhamhaeng Hospital Public Company Limited in the amount of THB 3,723,825,000, representing 430,500,000 shares. As a result, Ramkhamhaeng Hospital Public Company Limited’s shareholding in THG increased from 24.59% to 49.99% as of 22 August 2025. THG utilized the entire proceeds from the capital increase to fully repay borrowings from financial institutions. |
September 2025 | THG received proceeds from the Rights Offering to existing shareholders in the amount of THB 2,555,934,800, representing 511,186,960 newly issued ordinary shares, as of 24 September 2025. The Company utilized the proceeds in line with the objectives of the capital increase, including the repayment of borrowings from financial institutions, partial early redemption of debentures, and allocation as working capital. |
October to November 2025 | THG approved a capital increase in Thonburi Wellbeing through Rights Offering. THG subscribed to 409,999,994 newly issued ordinary shares in proportion to its shareholding, at a par value of THB 10 per share, totaling THB 4,100 million. The transaction was completed on 28 November 2025, resulting in THG maintaining its shareholding at 99.99%. Thonburi Wellbeing Company Limited utilized the entire proceeds to fully repay intercompany loans owed to THG. |
November 2025 | Trang Vejakij Company Limited (Thonburi Trang Hospital) opened its Radiology Center on 17 November 2025. |
December 2025 | THG resolved to dissolve its wholly owned subsidiary, Thonburi Partners Pte. Limited, in which THG held a 100% shareholding with a registered capital of SGD 1,000,000, on 29 January 2025. The dissolution was completed and officially registered on 18 December 2025. |
December 2025 | THG approved a capital increase in its subsidiary, Thonburi Bamrungmuang Hospital, through a rights offering to existing shareholders. THG subscribed to 460,001,900 newly issued ordinary shares in proportion to its shareholding, at a par value of THB 5 per share, totaling THB 2,300,009,500. The transaction was completed on 22 December 2025, increasing THG’s shareholding from 95.14% to 98.26%. Thonburi Bamrungmuang Hospital utilized the entire proceeds to fully repay intercompany borrowings owed to THG. |
May to December 2025 | THG resolved to dissolve its subsidiary, Telehealth Care Company Limited, in which THG held an 85% shareholding with paid-up capital of THB 50,000,000, on 13 May 2025. The Extraordinary General Meeting of Shareholders of Telehealth Care Company Limited approved the dissolution on 22 December 2025, and the dissolution was completed and officially registered on 26 December 2025. |

